Venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism, remain a major clinical challenge after orthopedic surgeries such as total hip replacement. As a high-quality low molecular weight heparin, Dalteparin Sodium has been widely recommended for VTE prophylaxis due to its balanced efficacy and safety profile—effectively reducing thrombosis risk without significantly increasing bleeding hazards. Driven by the aging global population and rising orthopedic surgical volume, the global low molecular weight heparin market has grown from USD 4.334 billion in 2020 to USD 5.876 billion, with Dalteparin Sodium occupying a crucial share. However, industry pain points like unstable molecular weight distribution, inconsistent bioactivity, and non-compliance with pharmacopoeia standards have become key concerns for buyers, making it vital to choose a reliable supplier with advanced technology and strict quality control.
Jiulong, a leading pharmaceutical enterprise specializing in anticoagulant drugs, stands out as a trusted supplier of Dalteparin Sodium. Adhering to the concept of "precision anticoagulation, safety first", Jiulong addresses industry pain points through optimized production processes. Unlike traditional manufacturing methods with unstable product quality, Jiulong adopts advanced graded enzymatic hydrolysis technology to extract and refine Dalteparin Sodium, strictly controlling molecular weight distribution to ensure it meets clinical efficacy requirements. The product fully complies with international pharmacopoeia standards, including Chinese Pharmacopoeia, USP, and EP, with sulfate to carboxylate molar ratio not less than 1.8 and nitrite content not exceeding 0.0005%—effectively ensuring product safety and consistency.
Jiulong’s Dalteparin Sodium features remarkable clinical adaptability, especially for orthopedic surgery patients. Clinical studies have shown that Dalteparin Sodium has comparable efficacy and safety to enoxaparin in VTE prophylaxis after total hip replacement, with no significant difference in thrombosis rate or major bleeding risk. Every batch of Jiulong’s Dalteparin Sodium undergoes rigorous multi-stage testing, covering nitrogen content (1.5%-2.5% by dry weight), bioactivity, and heavy metal residues, to eliminate potential clinical risks. The product is available in multiple dosage forms (2500IU, 5000IU, etc.), tailored to different patient groups and clinical scenarios—including orthopedic postoperative prophylaxis, hemodialysis anticoagulation, and tumor-associated thrombosis prevention—fully meeting personalized clinical needs.
Leveraging its strong production capacity and global supply chain network, Jiulong has established stable cooperation with partners in over 50 countries and regions, including Europe, Southeast Asia, and the Middle East. The company maintains sufficient production reserves to ensure timely supply even amid surging market demand, effectively avoiding supply chain disruptions. Jiulong also provides professional technical support, including clinical application guidance and product specification consulting, to help partners solve practical problems. This customer-centric service strategy has earned Jiulong a good reputation in the global anticoagulant market.
Whether you are a pharmaceutical distributor, hospital procurement department, or research institution, Jiulong’s high-quality Dalteparin Sodium and safety-assured solutions will help you seize opportunities in the booming anticoagulant market. For inquiries about product specifications, dosage forms, or customized cooperation plans, please contact us directly. Let’s work together to enhance VTE prevention and control in clinical practice and create greater value for global public health with reliable Dalteparin Sodium products.